Company Overview
Position Overview
Immunome is seeking a talented and passionate cancer biologist with experience developing and championing novel therapeutic concepts in a fast-paced scientifically rigorous environment. The person in this position will be challenged to leverage their deep understanding of cancer biology, drug resistance mechanisms, and pharmacology to engineer the next generation of ADC therapeutics. In partnership with cross-functional teams across the company, they will lead the discovery, optimization, and nomination of new drug candidates for clinical development.
Responsibilities
- Apply extensive knowledge of oncology and ADC pharmacology to formulate new therapeutic concepts and guide their development.
- Lead preclinical discovery efforts for novel ADC technologies from linker payload discovery through target selection, therapeutic design, in vitro and in vivo characterization, optimization, candidate nomination, and IND-enabling studies.
- Ensure seamless cross-functional integration with colleagues in antibody discovery, chemistry, translational sciences, program management, CMC, and clinical development and represent the biology perspective in discussions with other functional areas.
- Stay abreast of the latest scientific developments and trends in ADC technologies and integrate relevant advancements into program strategies.
- Contribute to patent filings, publications, and external presentations.
- Contribute to the preparation and review of regulatory documents, including IND submissions, ensuring compliance with regulatory requirements.
Qualifications
- Ph.D. in Cell Biology, Cancer Biology, Pharmacology, Chemical Biology, Biochemistry, Immunology, or related fields.
- A minimum of 4+ years of project leadership experience in biotech/pharmaceutical industry, with a focus on preclinical drug development in immunology or oncology.
- Experience designing and interpreting in vitro and in vivo ADC assays, including target expression/internalization, payload mechanism of action, PK/PD and efficacy studies.
- Deep understanding of ADC design principles including the impact of target, antibody, and linker-payload properties on ADC safety and efficacy.
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).
Skills Required
- Ph.D. in Cell Biology, Cancer Biology, Pharmacology, Chemical Biology, Biochemistry, Immunology, or related fields
- Minimum of 4+ years of project leadership experience in biotech/pharmaceutical industry
- Experience designing and interpreting in vitro and in vivo ADC assays
- Deep understanding of ADC design principles
What We Do
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
